EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS
Value in Health · 2026-06 · 29 (6) · S72
DOI: 10.1016/j.jval.2026.03.342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Ifechukwu B. Nwogu und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Nwogu, I. B., Kreif, N., Khan, H., Etzioni, R., & Carlson, J. J. (2026). EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS. Value in Health, 29(6), S72. https://doi.org/10.1016/j.jval.2026.03.342
Vancouver
Nwogu IB, Kreif N, Khan H, Etzioni R, Carlson JJ. EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS. Value in Health. 2026;29(6):S72. doi:10.1016/j.jval.2026.03.342
BibTeX
@article{Nwogu2026,
author = {Nwogu, Ifechukwu B. and Kreif, Noemi and Khan, Hiba and Etzioni, Ruth and Carlson, Josh J.},
title = {EE46 COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S72},
doi = {10.1016/j.jval.2026.03.342}
}
EUVIMED